证券时报e公司讯,今天,晶泰科技宣布与新加坡国立癌症中心(National Cancer Centre Singapore,NCCS)以及杜克-新加坡国立大学医学院(Duke-NUS Medical School, Duke-NUS)开展 AI 新药发现合作,晶泰科技将运用其 AI 和自动化实验驱动的多肽研发设计平台,针对 NCCS 选定的肾透明细胞癌(Clear Cell Renal Cell ...
TLX250-CDx is an investigational PET 3 drug product for the non-invasive diagnosis and characterization of clear cell renal cell carcinoma (ccRCC), the most common and aggressive form of kidney cancer ...
In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...
Telix Pharmaceuticals Limited (TLX) said that it has submitted its Biologics License Application (BLA) to the U.S. Food and Drug ...
Telix CEO Chris Behrenbruch has been awarded a 68% base pay rise ahead of expected FDA approval of its kidney cancer ...
Relevance section written by JCO Clinical Cancer Informatics Associate Editor Ziad Bakouny, MD, MSc. The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) prognostic model was ...
Shares of Bristol Myers Squibb ($BMY) were in the spotlight on Friday after the U.S. Food and Drug Administration approved an ...
Opdivo Qvantig is the first subcutaneously administered PD-1 inhibitor approved by the FDA. It is expected to be available in ...
Opdivo Qvantig is approved for solid tumors, including melanoma, renal cell carcinoma, and non-small cell lung cancer. The ...
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T ...